A Patient With Autoimmune Liver Disease on Steroids: Screening and Treatment of Bone Disease
A 38-year-old woman presented with clinical and biochemical features of acute hepatitis. A tentative diagnosis of type 1 autoimmune hepatitis was made on the basis of positive autoantibodies (antinuclear and anti-smooth muscle), hypergammaglobulinemia, and hypocomplementemia. She was started on oral prednisone 40 mg/day, tapered over the subsequent 12 weeks to a maintenance dose of 7.5 mg/day. Azathioprine 100 mg/day then was introduced for its steroid-sparing effect, and she was started on vitamin D and calcium supplements. Her bone density (after 18 months of treatment) revealed a spine Z-score of −1.2 and a hip Z-score of −.8. She has never broken any bones, does not smoke, takes oral contraceptives, and has no other major risk factors for osteoporosis. What is the interpretation of the bone density Z-scores? How can this patient’s fracture risk be minimized, and how should she be monitored?
Department of Medicine, St. Boniface General Hospital, Winnipeg, Manitoba, Canada
Address requests for reprints to: William D. Leslie, MD, MSc, Department of Medicine (C5121), St. Boniface General Hospital, 409 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6. fax: (204) 237-2007.
In the past 5 years William D. Leslie has received speaker fees, research honoraria, and unrestricted research grants from Merck Frosst Canada Ltd. (the manufacturer of alendronate); research honoraria and unrestricted educational grants from Sanofi-Aventis and Proctor & Gamble Pharmaceuticals Canada, Inc. (the manufacturer of risedronate).